Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
Authors
Keywords
Melanoma, Immunotherapy, Combination, Nivolumab, Pembrolizumab, Ipilimumab, Toxicity
Journal
EUROPEAN JOURNAL OF CANCER
Volume 153, Issue -, Pages 168-178
Publisher
Elsevier BV
Online
2021-06-25
DOI
10.1016/j.ejca.2021.04.045
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors
- (2020) Nicole A. Romanski et al. EUROPEAN JOURNAL OF CANCER
- Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
- (2020) Caroline Robert et al. EUROPEAN JOURNAL OF CANCER
- Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes
- (2019) Venessa H M Tsang et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma
- (2019) Robert Mason et al. Pigment Cell & Melanoma Research
- Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
- (2018) Alexander N. Shoushtari et al. JAMA Oncology
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
- (2017) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) R. Dummer et al. ANNALS OF ONCOLOGY
- Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).
- (2015) Jedd D. Wolchok et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- New drugs in melanoma: It’s a whole new world
- (2011) Alexander M.M. Eggermont et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now